Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex

NCU Institutional Repository > 總教學中心委員會 > 通識教育中心 > 期刊論文 > Item 987654321/105801

請使用永久網址來引用或連結此文件: https://ir.lib.ncu.edu.tw/handle/987654321/105801

題名:	Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex
作者:	吳忻怡;Lin, Yu-Ling;Chen, Chia-Hung;Wu, Hsin-Yi;Tsai, Nu-Man;Jian, Ting-Yan;Chang, Yuan-Ching;Lin, Chi-Hsin;Wu, Chih-Hsiung;Hsu, Fei-Ting;Leung, Ting Kai;Liao, Kuang-Wen
貢獻者:	總教學中心通識教育中心
關鍵詞:	Administration, Cutaneous;Analysis;Animals;Biotechnology;Breast - drug effects;Breast cancer;Breast Neoplasms - drug therapy;Care and treatment;Cell Line, Tumor;Cell Proliferation - drug effects;Chemistry;Chemistry and Materials Science;Complications and side effects;Drug Delivery Systems - methods;Female;Health aspects;HEK293 Cells;Humans;Liposomes - administration & dosage;MCF-7 Cells;Menopause;Mice;Mice, Nude;Molecular Medicine;Nanotechnology;Polyethylene Glycols - administration & dosage;Polyethyleneimine - administration & dosage;Polyethyleneimine - analogs & derivatives;Postmenopausal women;Tamoxifen;Tamoxifen - administration & dosage
日期:	2016-02-19
上傳時間:	2026-04-23 12:53:25 (UTC+8)
出版者:	BioMed Central Ltd.;London: BioMed Central
摘要:	摘要： Background Tamoxifen is currently used for the treatment of both early and advanced estrogen receptor (ER) positive breast cancer in pre- and post-menopausal women. However, using tamoxifen routinely to inhibit endogenous or exogenous estrogen effects is occasionally difficult because of its potential side effects. Objectives The aim of this study is to design a local drug delivery system to encapsulate tamoxifen for observing their efficacy of skin penetration, drug accumulation and cancer therapy. Methods A cationic liposome-PEG-PEI complex (LPPC) was used as a carrier for the encapsulation of tamoxifen and forming ‘LPPC/TAM’ for transdermal release. The cytotoxicity of LPPC/TAM was analyzed by MTT. The skin penetration, tumor growth inhibition and organ damages were measured in xenograft mice following transdermal treatment. Results LPPC/TAM had an average size less than 270 nm and a zeta-potential of approximately 40 mV. LPPC/TAM displayed dramatically increased the cytotoxic activity in all breast cancer cells, especially in ER-positive breast cancer cells. In vivo, LPPC drug delivery helped the fluorescent dye penetrating across the skim and accumulating rapidly in tumor area. Administration of LPPC/TAM by transdermal route inhibited about 86 % of tumor growth in mice bearing BT474 tumors. This local treatment of LPPC/TAM did not injury skin and any organs. Conclusion LPPC-delivery system provided a better skin penetration and drug accumulation and therapeutic efficacy. Therefore, LPPC/TAM drug delivery maybe a useful transdermal tool of drugs utilization for breast cancer therapy. 其他題名： J Nanobiotechnol 其他題名： J Nanobiotechnology 出版者： London: BioMed Central 出版日期： 2016-02-19 出處： Journal of nanobiotechnology, 2016-02, Vol.14 (1), p.11-11, Article 11 資源來源： Publicly Available Content Database 版權： Lin et al. 2016 版權： COPYRIGHT 2016 BioMed Central Ltd. 版權： Copyright BioMed Central 2016 識別號： ISSN: 1477-3155 識別號： EISSN: 1477-3155 識別號： DOI: 10.1186/s12951-016-0163-3 識別號： PMID: 26892504
顯示於類別:	[通識教育中心] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	31	檢視/開啟

在NCUIR中所有的資料項目都受到原著作權保護.

社群 sharing

資料載入中.....